135 related articles for article (PubMed ID: 7765173)
21. Engineering the substrate specificity of rhizopuspepsin: the role of Asp 77 of fungal aspartic proteinases in facilitating the cleavage of oligopeptide substrates with lysine in P1.
Lowther WT; Majer P; Dunn BM
Protein Sci; 1995 Apr; 4(4):689-702. PubMed ID: 7613467
[TBL] [Abstract][Full Text] [Related]
22. Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.
Eizert H; Bander P; Bagossi P; Sperka T; Miklóssy G; Boross P; Weber IT; Tözsér J
J Virol; 2008 Oct; 82(20):10111-7. PubMed ID: 18701588
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of substrate specificity in the serine proteases.
Perona JJ; Craik CS
Protein Sci; 1995 Mar; 4(3):337-60. PubMed ID: 7795518
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
25. Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates.
Tözsér J; Bagossi P; Boross P; Louis JM; Majerova E; Oroszlan S; Copeland TD
Eur J Biochem; 1999 Oct; 265(1):423-9. PubMed ID: 10491200
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of the dimerization of retroviral proteases: the "fireman's grip" and dimerization.
Ingr M; Uhlíková T; Strísovský K; Majerová E; Konvalinka J
Protein Sci; 2003 Oct; 12(10):2173-82. PubMed ID: 14500875
[TBL] [Abstract][Full Text] [Related]
27. X-ray structures of retroviral proteases and their inhibitor-bound complexes.
Ringe D
Methods Enzymol; 1994; 241():157-77. PubMed ID: 7854176
[No Abstract] [Full Text] [Related]
28. Analysis of substrate cleavage by recombinant protease of human T cell leukaemia virus type 1 reveals preferences and specificity of binding.
Daenke S; Schramm HJ; Bangham CR
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2233-9. PubMed ID: 8077922
[TBL] [Abstract][Full Text] [Related]
29. Evolutionarily conserved functional mechanics across pepsin-like and retroviral aspartic proteases.
Cascella M; Micheletti C; Rothlisberger U; Carloni P
J Am Chem Soc; 2005 Mar; 127(11):3734-42. PubMed ID: 15771507
[TBL] [Abstract][Full Text] [Related]
30. Engineering of the substrate-binding region of the subtilisin-like, cell-envelope proteinase of Lactococcus lactis.
Siezen RJ; Bruinenberg PG; Vos P; van Alen-Boerrigter I; Nijhuis M; Alting AC; Exterkate FA; de Vos WM
Protein Eng; 1993 Nov; 6(8):927-37. PubMed ID: 8309942
[TBL] [Abstract][Full Text] [Related]
31. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
32. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates.
Tomasselli AG; Heinrikson RL
Methods Enzymol; 1994; 241():279-301. PubMed ID: 7854182
[No Abstract] [Full Text] [Related]
33. Subsite preferences of retroviral proteinases.
Dunn BM; Gustchina A; Wlodawer A; Kay J
Methods Enzymol; 1994; 241():254-78. PubMed ID: 7854181
[No Abstract] [Full Text] [Related]
34. Importance of the N terminus of rous sarcoma virus protease for structure and enzymatic function.
Schatz GW; Reinking J; Zippin J; Nicholson LK; Vogt VM
J Virol; 2001 May; 75(10):4761-70. PubMed ID: 11312348
[TBL] [Abstract][Full Text] [Related]
35. Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation.
Davis DA; Brown CA; Newcomb FM; Boja ES; Fales HM; Kaufman J; Stahl SJ; Wingfield P; Yarchoan R
J Virol; 2003 Mar; 77(5):3319-25. PubMed ID: 12584357
[TBL] [Abstract][Full Text] [Related]
36. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.
Ridky TW; Kikonyogo A; Leis J; Gulnik S; Copeland T; Erickson J; Wlodawer A; Kurinov I; Harrison RW; Weber IT
Biochemistry; 1998 Sep; 37(39):13835-45. PubMed ID: 9753473
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor.
Katoh I; Yasunaga T; Ikawa Y; Yoshinaka Y
Nature; 1987 Oct 15-21; 329(6140):654-6. PubMed ID: 2821409
[TBL] [Abstract][Full Text] [Related]
38. Selection of Streptomyces griseus protease B mutants with desired alterations in primary specificity using a library screening strategy.
Sidhu SS; Borgford TJ
J Mol Biol; 1996 Mar; 257(2):233-45. PubMed ID: 8609620
[TBL] [Abstract][Full Text] [Related]
39. Linkers for improved cleavage of fusion proteins with an engineered alpha-lytic protease.
Lien S; Milner SJ; Graham LD; Wallace JC; Francis GL
Biotechnol Bioeng; 2001 Aug; 74(4):335-43. PubMed ID: 11410858
[TBL] [Abstract][Full Text] [Related]
40. [Conserved interactions of the active carboxyls in pepsin-like enzymes and retroviral proteases].
Andreeva NS; Popov ME
Mol Biol (Mosk); 2002; 36(5):939-44. PubMed ID: 12391858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
